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OBJECTIVES We sought to evaluate the relationship between the level of kidney function, level of
hematocrit and their interaction on all-cause mortality in patients with left ventricular (LV)
dysfunction.
BACKGROUND Anemia and reduced kidney function occur frequently in patients with heart failure. The level
of hematocrit and its relationship with renal function have not been evaluated as risk factors
for mortality in patients with LV dysfunction.
METHODS We retrospectively examined the Studies Of LV Dysfunction (SOLVD) database. Glomer-
ular filtration rate (GFR) was predicted using a recently validated formula. Kaplan-Meier
survival analyses were used to compare survival times between groups stratified by level of
kidney function (predicted GFR) and hematocrit. Cox proportional-hazards regression was
used to explore the relationship of survival time to level of kidney function, hematocrit and
their interaction.
RESULTS Lower GFR and hematocrit were associated with a higher prevalence of traditional
cardiovascular risk factors. In univariate analysis, reduced kidney function and lower
hematocrit, in men and in women, were risk factors for all-cause mortality (p , 0.001 for
both). After adjustment for other factors significant in univariate analysis, a
10 ml/min/1.73 m2 lower GFR and a 1% lower hematocrit were associated with a 1.064 (95%
CI: 1.033, 1.096) and 1.027 (95% CI: 1.015, 1.038) higher risk for mortality, respectively. At
lower GFR and lower hematocrit, the risk was higher (p 5 0.022 for the interaction) than
that predicted by both factors independently.
CONCLUSIONS Decreased kidney function and anemia are risk factors for all-cause mortality in patients with
LV dysfunction, especially when both are present. These relationships need to be confirmed
in additional studies. (J Am Coll Cardiol 2001;38:955–62) © 2001 by the American College
of Cardiology
Reduced kidney function and anemia occur frequently in
patients with heart failure (HF) (1–4). In fact, as many as
25% to 50% of patients with HF have creatinine clearances
less than 60 ml/min to 75 ml/min (4,5), while mean
hemoglobin levels range from 10 g/dl to 12 g/dl in patients
with HF (1,2,6).
Although prior studies have suggested that reduced
kidney function may be a risk factor for all-cause mortality
(4,5), these studies did not provide a quantitative estimate of
the relationship between the level of kidney function to
mortality. These studies also did not consider the indepen-
dent contribution of anemia, a known complication of
kidney disease.
Anemia is a well-recognized risk factor for left ventricular
(LV) hypertrophy, de novo and recurrent HF and all-cause
mortality in the end-stage renal disease (ESRD) population
(7). Patients with ESRD are anemic secondary to erythro-
poietin deficiency. Anemia also occurs in patients with less
severe reduction in kidney function. Treatment with eryth-
ropoietin is feasible in patients with or without ESRD.
Therefore, the evaluation of anemia as a risk factor in
patients with LV dysfunction is important from a mecha-
nistic as well as a treatment standpoint.
One recent study suggested that treatment of mild-to-
moderate anemia with erythropoietin may improve morbid-
ity in patients with severe HF (8). However, no studies have
evaluated the level of hematocrit as a risk factor for mortality
in HF. Furthermore, no studies have evaluated patients with
a wider range of LV dysfunction. We hypothesized that
there may be a relationship between the level of kidney
function, level of hematocrit and mortality in patients with
LV dysfunction.
The Studies Of Left Ventricular Dysfunction (SOLVD)
was a large randomized controlled trial that enrolled pa-
tients with ejection fraction of #35%. The study sample
included patients with a wide range of hematocrit and level
of kidney function. The current study evaluates the inde-
pendent effect of hematocrit level on mortality and extends
prior analyses of SOLVD by estimating kidney function
primarily as a continuous variable. In so doing, we are also
From the *Division of Cardiology, Department of Medicine, New England
Medical Center, Tufts University School of Medicine, Boston, Massachusetts; the
†Department of Community Health, Tufts University School of Medicine, Boston,
Massachusetts; and the ‡Division of Nephrology, Department of Medicine, New
England Medical Center, Tufts University School of Medicine, Boston, Massachu-
setts. Supported by Amgen Inc., Thousand Oaks, California and grants: K23
NIDDK 02904-01, RO1 NIDDK 53869-02 and MO1 RR00054. Presented, in part,
at the 32nd and 33rd Annual Meetings of the American Society of Nephrology in
Miami, Florida, November 5 to 8, 1999, and Toronto, Canada, October 13 to 16,
2000, respectively.
Manuscript received February 23, 2001; revised manuscript received May 21, 2001,
accepted June 11, 2001.
Journal of the American College of Cardiology Vol. 38, No. 4, 2001
© 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00
Published by Elsevier Science Inc. PII S0735-1097(01)01470-X
able to evaluate the relationship (interaction) between the
level of hematocrit and kidney function on all-cause mor-
tality.
METHODS
Design. The SOLVD was a multicenter, randomized,
double-blind, placebo-controlled trial evaluating the effect
of enalapril on survival in patients with LV ejection fraction
#35%. Patients were stratified by the presence of symp-
toms. Asymptomatic patients were enrolled in the SOLVD
prevention trial (n 5 4,228); symptomatic patients were
enrolled in the SOLVD treatment trial (n 5 2,569). Both
groups of patients were included in the current analysis
(9–11).
Exclusion criteria for the prevention trial and the treat-
ment trial included patients with a serum creatinine
.2.5 mg/dl, recent myocardial infarction, unstable angina,
severe pulmonary disease, uncontrollable hypertension, ma-
jor cerebrovascular disease or suspected renal artery stenosis
(9–11).
This study is a retrospective analysis of the relationship of
survival time to level of kidney function and hematocrit and
their interaction. Baseline serum creatinine and hematocrit
were measured in 6,635 and 6,563 patients, respectively.
Glomerular filtration rate (GFR) was computed in 6,630
patients using a prediction formula derived from the Mod-
ification of Diet in Renal Disease (MDRD) study (12,13):
GFR 5 186 3 (serum creatinine21.154) 3 (age20.203) 3
1.212 (if black) 3 0.742 (if female). Serum creatinine is
measured in mg/dl, age in years, and GFR is expressed as
ml/min/1.73 m2.
Baseline characteristics included patient demographics
(age, ethnicity, gender); past medical history (diabetes,
hypertension, myocardial infarction, atrial fibrillation, cere-
brovascular disease, abdominal aortic aneurysm and past or
current smoking); measures of cardiac function (ejection
fraction, New York Heart Association [NYHA] functional
class, etiology of LV dysfunction, orthopnea and paroxysmal
nocturnal dyspnea); previous medication use (beta-
adrenergic blocking agents, diuretics, digoxin, vasodilators,
nitrates, captopril, potassium replacement, anticoagulants,
antiarrhythmic agents and calcium channel blockers); trial
assignment (treatment vs. prevention); randomization to
enalapril versus placebo; laboratory variables (serum potas-
sium, sodium, creatinine, blood urea nitrogen and hemato-
crit) and physical examination (systolic blood pressure,
diastolic blood pressure, heart rate, S3 gallop, jugular venous
pressure, rales and edema).
The end point of all-cause mortality, reached by 1,565
(23.6%) of the subjects, was chosen because prior analyses
demonstrated that over 85% of deaths were due to cardio-
vascular disease (10,11).
Statistical analysis. Means, standard deviations and per-
centages were used to describe the baseline characteristics.
Initially, the data were stratified into three groups by level of
kidney function (GFR ,60 ml/min/1.73 m2, 60 ml/min/
1.73 m2 to 75 ml/min/1.73 m2 and .75 ml/min/1.73 m2)
and by level of hematocrit (,35, 35 to 39 and $40).
Chi-square tests (testing for linear trend where appropriate)
and analysis of variance (ANOVA) were used to compare
baseline data for each of these groupings. The cut-points
for the three groups were chosen to reflect clinically
meaningful values. Additionally, a Pearson correlation was
used to evaluate the relationship of hematocrit to predicted
GFR.
Kaplan-Meier survival analysis was used to compare
survival times between the three groups stratified by level of
kidney function (measured as predicted GFR) and by
hematocrit. Men and women were analyzed separately for
hematocrit. The log-rank statistic was used to test for
differences between groups.
Cox proportional-hazards regression (stepwise, likelihood
ratio, p , 0.05 for inclusion) was used to explore the
relationship of survival time to the primary variables pre-
dicted GFR and hematocrit. A multivariable model was
developed using predicted GFR and hematocrit. Regres-
sions were run for primary variables alone and for these
variables adjusted for those baseline variables that were
significantly and independently related to survival time in
univariate analyses (p , 0.05). Squares of GFR and hemat-
ocrit were calculated in order to search for nonlinear
relationships. We also evaluated the product of GFR and
hematocrit to search for interactions between the primary
variables. The relative risk of survival for different levels of
kidney function and hematocrit were estimated from the
hazard ratios.
Subgroup analysis was performed to evaluate whether the
adjusted relative risk for mortality due to a change in
hematocrit or a change in level of kidney function was
different in patients treated with enalapril versus placebo.
Data were entered into SPSS, Version 10, for analyses;
testing was two-sided, and p values , 0.05 were considered
significant.
RESULTS
Baseline characteristics. The baseline characteristics of
the patients are summarized in Table 1 and Figure 1A and
1B. Mean serum creatinine was 1.2 mg/dl with a range of
0.5 mg/dl to 2.4 mg/dl; mean predicted GFR was
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
ESRD 5 end-stage renal disease
GFR 5 glomerular filtration rate
HF 5 heart failure
LV 5 left ventricle or left ventricular
MDRD 5 Modification of Diet in Renal Disease
NYHA 5 New York Heart Association
SOLVD 5 Studies Of Left Ventricular Dysfunction
956 Al-Ahmad et al. JACC Vol. 38, No. 4, 2001
Kidney Disease and Anemia in Ventricular Dysfunction October 2001:955–62
Ta
bl
e
1.
B
as
el
in
e
C
ha
ra
ct
er
is
tic
s
of
th
e
St
ud
y
P
op
ul
at
io
n
by
L
ev
el
of
K
id
ne
y
Fu
nc
tio
n
an
d
H
em
at
oc
ri
t
C
ha
ra
ct
er
is
ti
cs
A
ll
(n
5
6,
63
5)
L
ev
el
of
K
id
ne
y
F
un
ct
io
n
(G
F
R
m
l/
m
in
/1
.7
3
m
2 )
L
ev
el
of
H
em
at
oc
ri
t
(%
)
<
60
(n
5
2,
10
6)
60
–7
5
(n
5
2,
13
3)
>
75
(n
5
2,
39
1)
p
V
al
ue
<
35
(n
5
29
0)
35
–3
9
(n
5
1,
14
5)
>
40
(n
5
5,
12
8)
p
V
al
ue
D
em
og
ra
ph
ic
s
A
ge
60
(1
0.
3)
65
(8
.1
)
60
(9
.7
)
56
(1
0.
7)
,
0.
00
1
62
(1
1.
1)
60
(1
0.
0)
59
(1
0.
2)
,
0.
00
1
G
en
de
r
(%
m
al
e)
86
80
89
89
,
0.
00
1
69
72
90
,
0.
00
1
E
th
ni
c
or
ig
in
(%
w
hi
te
)
84
87
86
81
,
0.
00
1
77
78
86
,
0.
00
1
E
je
ct
io
n
fr
ac
tio
n
27
(6
.3
)
27
(6
.3
)
27
(6
.4
)
27
(6
.2
)
0.
04
27
(6
.1
)
27
(6
.2
)
27
(6
.3
)
0.
93
1
E
tio
lo
gy
of
L
V
dy
sf
un
ct
io
n
(%
is
ch
em
ic
)
79
79
81
77
0.
01
5
76
77
80
0.
04
7
N
Y
H
A
cl
as
s
,
0.
00
1
,
0.
00
1
I
46
36
49
52
37
39
48
II
42
46
40
40
43
43
42
II
I
an
d
IV
12
18
11
8
20
19
10
T
ri
al
as
si
gn
m
en
t
(%
tr
ea
tm
en
t)
38
49
34
31
,
0.
00
1
47
45
35
,
0.
00
1
T
re
at
m
en
t
as
si
gn
m
en
t
(%
en
al
ap
ri
l)
50
50
49
51
0.
58
49
49
50
0.
66
8
P
re
vi
ou
s
m
ed
ic
at
io
n
us
e
B
et
a-
bl
oc
ke
rs
18
15
19
20
,
0.
00
1
13
14
19
,
0.
00
1
D
iu
re
tic
42
56
39
34
,
0.
00
1
47
49
40
,
0.
00
1
D
ig
ox
in
33
39
31
29
,
0.
00
1
39
37
32
0.
00
1
A
nt
ia
rr
hy
th
m
ic
ag
en
ts
18
24
18
14
,
0.
00
1
26
18
17
0.
00
1
P
as
t
m
ed
ic
al
hi
st
or
y
H
yp
er
te
ns
io
n
39
46
37
34
,
0.
00
1
43
40
38
0.
13
4
D
ia
be
te
s
19
23
17
17
,
0.
00
1
27
23
18
0.
00
3
M
yo
ca
rd
ia
li
nf
ar
ct
io
n
75
74
78
74
0.
00
4
67
73
76
0.
00
2
P
hy
si
ca
le
xa
m
Sy
st
ol
ic
bl
oo
d
pr
es
su
re
(m
m
H
g)
12
5
(1
7.
0)
12
7
(1
8.
0)
12
5
(1
6.
6)
12
4
(1
6.
2)
,
0.
00
1
12
5
(1
8.
4)
12
4
(1
7.
6)
12
5
(1
6.
7)
0.
12
2
D
ia
st
ol
ic
bl
oo
d
pr
es
su
re
(m
m
H
g)
77
(9
.9
)
77
(1
0.
2)
78
(9
.7
)
78
(9
.7
)
0.
00
1
75
(1
0.
2)
76
(1
0.
0)
78
(9
.7
)
,
0.
00
1
L
ab
or
at
or
y
da
ta
C
re
at
in
in
e
(m
g/
dl
)
1.
18
(0
.3
)
1.
47
(0
.3
)
1.
17
(0
.1
)
0.
94
(0
.1
)
,
0.
00
1
1.
23
(0
.4
)
1.
20
(0
.3
)
1.
17
(0
.3
)
,
0.
00
1
H
em
at
oc
ri
t
43
(4
.5
)
42
(4
.7
)
43
(4
.4
)
43
(4
.3
)
,
0.
00
1
B
lo
od
ur
ea
ni
tr
og
en
(m
g/
dl
)
18
(6
.5
)
22
(7
.6
)
18
(5
.1
)
15
(4
.7
)
,
0.
00
1
21
19
18
,
0.
00
1
P
re
di
ct
ed
G
FR
(m
l/
m
in
/1
.7
3
m
2 )
70
(1
9.
3)
67
(2
1.
6)
67
(2
0.
6)
71
(1
8.
6)
,
0.
00
1
D
at
a
ar
e
di
sp
la
ye
d
as
m
ea
n
(S
D
)
or
%
.
G
FR
5
gl
om
er
ul
ar
fil
tr
at
io
n
ra
te
;L
V
5
le
ft
ve
nt
ri
cu
la
r;
N
Y
H
A
5
N
ew
Y
or
k
H
ea
rt
A
ss
oc
ia
tio
n.
957JACC Vol. 38, No. 4, 2001 Al-Ahmad et al.
October 2001:955–62 Kidney Disease and Anemia in Ventricular Dysfunction
70.4 ml/min/1.73 m2 with a range of 23 ml/min/1.73 m2 to
188 ml/min/1.73 m2, and mean hematocrit was 42.7% with
a range of 25% to 58%. Mean ejection fraction was 27%
with a range of 6% to 35%. The patients were predomi-
nantly white men, and ischemia was the cause of the LV
dysfunction in approximately 80% of cases.
A total of 32% of patients had predicted GFR
,60 ml/min/1.73 m2, while 22% and 4.3% of the cohort
had hematocrit #39 or ,35, respectively. The cohort,
therefore, included a significant percentage of patients with
reduced kidney function and anemia. The correlation be-
tween hematocrit and predicted GFR was weak but statis-
tically significant (r 5 0.084, p , 0.01).
Association of reduced kidney function and anemia with
other baseline factors. Reduced kidney function and ane-
mia were significantly associated with a variety of baseline
factors. Patients with lower GFR were older, had slightly
lower ejection fractions and higher blood pressure and were
more likely to be women, white and taking diuretics or
antiarrhythmic agents, have a higher prevalence of hyper-
tension, diabetes or NYHA class III or IV, were less likely
to be taking beta-blockers and less likely to be in the
prevention rather than treatment trial (Table 1). Patients
with lower hematocrit were more likely to be older, women,
non-white, have a higher prevalence of NYHA class III or
IV and diabetes, were less likely to be taking beta-blockers,
more likely to be taking diuretics, digoxin and antiarrhyth-
mic agents and more likely to be in the treatment rather
than prevention trial (Table 1).
Outcomes. Mean follow-up time was 33.4 months with a
range of 14.6 months to 62 months. Cardiovascular disease
accounted for 89% of the 1,565 deaths. Kaplan-Meier
survival analysis demonstrated that reduced kidney function
(Fig. 2, p , 0.001 by log-rank statistics) and lower
hematocrit in both men and women were risk factors for
all-cause mortality (Fig. 3A and B, p , 0.001 by log-rank
statistics).
After adjusting for variables significant in univariate
analysis (Table 2), lower hematocrit and lower predicted
GFR, each remained significant risk factors for all-cause
mortality. A 10 ml/min/1.73 m2 lower GFR was associated
with a 1.064 (95% CI: 1.033, 1.096) higher risk for
mortality. A 1% lower hematocrit was associated with a
1.027 (95% CI: 1.015, 1.038) higher risk for mortality. The
quadratic term did not significantly improve the prediction
of survival; thus, these relationships were best described by
linear equations.
Subgroup analysis of patients treated with enalapril versus
those treated with placebo revealed similar results in mul-
tivariable analysis. That is, in patients treated with enalapril,
a 10 ml/min/1.73 m2 lower GFR was associated with a
1.078 (1.031, 1.125; p 5 0.001) higher risk for mortality,
while a 1% lower hematocrit was associated with a 1.024
(1.007, 1.041; p 5 0.006) higher risk for mortality. In
patients treated with placebo, a 10 ml/min/1.73 m2 lower
GFR was associated with a 1.053 (1.009 to 1.099; p 5
0.017) higher risk for mortality, while a 1% lower hemato-
Figure 1. (A) Distribution of glomerular filtration rate (GFR) in the Study
Of Left Ventricular Dysfunction (SOLVD). Mean is 70 ml/min/1.73 m2,
with a standard deviation of 19.3 and n is 6,630. A total of 6.8% of patients
had a GFR of ,45 ml/min/1.73 m2, 25% between 45 ml/min/1.73 m2 to
60 ml/min/1.73 m2, 32.1% between 60 to 75 ml/min/1.73 m2, 21.7%
between 75 to 90 ml/min/1.73 m2 and 14.4% .90 ml/min/1.73 m2. (B)
Distribution of hematocrit in SOLVD. Mean is 43; SD is 4.49 and n is
6,563. A total of 4.3% of the patients have a hematocrit ,35%, 17.5%
between 35 and 39, 51.7% between 40 and 45, 23.1% between 45 and 50
and 3.3% . 50.
Figure 2. Kaplan-Meier survival analysis by level of glomerular filtration
rate (GFR).
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crit was associated with a 1.031 (1.014 to 1.047; p , 0.001)
higher risk for mortality.
There was a statistically significant interaction (p 5
0.022) between hematocrit and predicted GFR on all-cause
mortality (Table 2). Thus, a lower level of both hematocrit
and GFR was associated with higher all-cause mortality
than expected from the sum of the individual effects. This is
illustrated in Table 3. At high levels of hematocrit, the effect
of lower GFR is not as large as it is at low levels of
hematocrit. Conversely, at high levels of GFR, the effect of
a decline in hematocrit is not as large as it is at low levels of
GFR. However, at low levels of both GFR and hematocrit,
the combined effect is larger than the sum of the individual
effects. For example, at a GFR of 45 ml/min/1.73 m2 and a
hematocrit of 50%, the standardized relative risk is 1.0,
while at a GFR of 90 ml/min/1.73 m2 and a hematocrit of
35%, the standardized relative risk for mortality is 1.1.
However, at a GFR of 45 ml/min/1.73 m2 and a hematocrit
of 35%, the relative risk is 1.8.
Figure 3. (A) Kaplan-Meier survival analysis by level of hematocrit (Hct)
in men. (B) Kaplan Meier survival analysis by level of Hct in women.
Table 2. Results of Unadjusted and Adjusted Cox Regression of All-Cause Mortality by Predicted GFR and Hematocrit
Model Factor
Unadjusted Adjusted*
RR CI p Value RR CI p Value
Predicted GFR for each
10 ml/min/1.73 m2 2
1.157 1.125, 1.192 , 0.001 1.067 1.035, 1.100 , 0.001
Hematocrit for each 1% 2 1.038 1.027, 1.049 , 0.001 1.028 1.016, 1.040 , 0.001
Model† without interaction Predicted GFR for each
10 ml/min/1.73 m2 2
As above 1.064 1.033, 1.096 , 0.001
Hematocrit for each 1% 2 As above 1.027 1.015, 1.038 , 0.001
Model‡ with interaction¶ Predicted GFR for each
10 ml/min/1.73 m2 2
— 1.416§ 1.106, 1.815 0.006
Hematocrit for each 1% 2 — 1.074\ 1.032, 1.119 , 0.001
Interaction term (product
hematocrit 3 predicted
GFR as above)
— 1.007 1.001, 1.013 0.022
*Adjustment is for baseline variables that were univariate predictors of mortality (gender, treatment assignment, trial assignment, NYHA functional class, ejection fraction,
presence of hypertension, cause of left ventricular dysfunction, history of myocardial infarction, presence of diabetes, beta-blocker, digoxin and diuretic use; †Model adjusts for
predicted GFR and hematocrit in addition to baseline variables; ‡Model including the interaction term hematocrit multiplied by predicted GFR; §RR for GFR when
hematocrit 5 0%; \RR for hematocrit when GFR 5 0 ml/min/1.73 m2; ¶RR (CI) for other baseline variables that were significant in multivariable analysis including the
interaction term: age (per one year increase), 1.015 (1.010, 1.021); gender (reference 5 female), 0.784 (0.678, 0.908); treatment assignment (reference 5 control), 0.897 (0.811,
0.991); NYHA functional class (per unit class increase), 1.355 (1.255, 1.464); ejection fraction (per 1% increase), 0.963 (0.955, 0.970); presence of diabetes (reference 5 no),
1.246 (1.106, 1.403); use of beta-blockers (reference 5 no), 0.829 (0.701, 0.979); use of digoxin (reference 5 no), 1.409 (1.257, 1.580) and use of diuretics (reference 5 no),
1.385 (1.221, 1.570).
CI 5 95% confidence intervals for the relative risk (RR); GFR 5 predicted glomerular filtration rate; NYHA 5 New York Heart Association.
Table 3. Standardized* RR for All-Cause Mortality Predicted
by Level of GFR and Hematocrit (Including the
Interaction Term)
GFR
(ml/min/1.73 m2)
Hematocrit (%)
35 40 45 50
30 2.1 1.7 1.3 1.0
45 1.8 1.5 1.2 1.0
60 1.5 1.3 1.1 1.0
75 1.3 1.2 1.1 1.0
90 1.1 1.1 1.0 1.0
*Values are standardized to reference levels of hematocrit of 45 and GFR of
90 ml/min/1.73 m2.
GFR 5 predicted glomerular filtration rate; RR 5 relative risk.
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DISCUSSION
Heart failure is a major public health problem in the U.S.
There are approximately 400,000 incident cases per year
(14), and deaths likely exceed 200,000 per year (15). Novel
approaches to the treatment of HF and its most common
cause, LV dysfunction, are, therefore, warranted.
Treatment modalities that have resulted in decreased
mortality in patients with HF include angiotensin-
converting enzyme (ACE) inhibitors (10), hydralazine in
combination with nitrates (16), beta-blockers (17) and,
more recently, spirinolactone (18). Although there has been
some improvement in survival in patients with HF, primar-
ily due to the introduction of ACE inhibitors, mortality
remains high.
Level of kidney function. A few (4,5), but not all (19,20),
studies have suggested that reduced kidney function may be
an important risk factor for mortality in patients with HF.
In one study (4), patients in the lowest quartile of creatinine
clearance had almost three times the risk of mortality of
patients in the highest quartile.
The level of GFR is usually regarded as the best overall
index of the level of kidney function. Serum creatinine is
determined by a number of factors, other than GFR, such as
gender, age, muscle mass and ethnicity and, therefore,
provides only a rough estimate of level of kidney function
(21). To provide a more accurate measure of kidney func-
tion, we estimated GFR using a recently validated formula
from the MDRD study (12,13). In patients with reduced
kidney function, this formula has been shown to be a more
accurate measure of kidney function than serum creatinine
or creatinine clearance estimated using either the Cockcroft
Gault equation or measured creatinine clearance using 24-h
urine collections (12).
Table 1 demonstrates that there is a high prevalence
of reduced kidney function in patients with LV dysfunc-
tion. Only 36% of the cohort had a predicted GFR
.75 ml/min/1.732. Reduced kidney function is associated
with a higher prevalence of risk factors for mortality, for
example lower ejection fraction and higher NYHA func-
tional class. This is consistent with previous studies that
suggest a higher prevalence of cardiac risk factors in patients
with greater reduction in kidney function (22,23).
Survival analysis demonstrates that level of kidney func-
tion is a significant risk factor for mortality in patients with
LV dysfunction. This is consistent with prior studies in-
cluding those of the SOLVD cohort (4,5). Multivariable
analysis confirms that reduced kidney function is an inde-
pendent risk factor for mortality in the entire study popu-
lation as well as in subgroups of patients treated with
enalapril versus placebo. Our analyses suggest that there is a
continuous relationship between the level of kidney function
and mortality, rather than a threshold value below which
reduced kidney function is a risk factor. That is, quadratic
terms did not significantly improve the prediction of sur-
vival.
We hypothesize three potential explanations why level of
kidney function may be a risk factor for all-cause mortality
in patients with HF. First, the level of kidney function may
be an additional marker of the level of cardiac function over
and above measures such as ejection fraction and NYHA
functional class. Second, reduced kidney function may be
associated with other risk factors for mortality that were not
measured in this study, such as hyperhomocysteinemia,
hyperfibrinogenemia and elevated C-reactive protein levels
(4,24–26). Third, reduced kidney function itself may be a
risk factor for progression of ventricular remodeling and
cardiac dysfunction. That is, kidney disease may worsen
sodium and fluid retention and result in progressive ventric-
ular dilation. Unfortunately, our retrospective analysis can-
not distinguish among these possibilities.
Level of hematocrit. The prevalence of anemia is high in
patients with HF (1,2,6). These mild levels of anemia have
not been evaluated as risk factors for mortality, although a
recent study demonstrated improved cardiac morbidity in
patients with severe HF treated with erythropoeitin (8). In
contrast with the limited data in patients without kidney
disease, it is well recognized that anemia is an independent
risk factor for the development of LV hypertrophy, de novo
and recurrent HF and all-cause mortality in patients with
ESRD (7). Furthermore, treatment of anemia with eryth-
ropoietin has improved many of the cardiac abnormalities
associated with HF in the ESRD population (27,28). The
prevalence of patients with both HF and anemia in the U.S.
exceeds the prevalence of ESRD; therefore, evaluation of
anemia as a potential independent risk factor in patients
with HF is clinically important.
Survival analysis also demonstrates that lower hematocrit
is a significant risk factor for mortality in both men and
women, and multivariable analysis confirms that reduced
hematocrit is an independent risk factor for mortality in the
entire study population, as well as in subgroups of patients
treated with enalapril versus placebo.
We hypothesize four potential explanations for this
finding. First, the level of hematocrit may be an additional
marker of cardiac function over and above measures such as
ejection fraction and NYHA functional class. That is, severe
HF, through as yet undefined mechanisms, may cause
anemia. Second, reduced hematocrit may be associated with
other risk factors for mortality that were not measured in
this study, such as elevated inhibitory cytokine levels or
malnutrition. The first two explanations are likely not
mutually exclusive. Third, reduced hematocrit may be a risk
factor for ischemia, a fact supported by animal studies that
have suggested that a small decrease in hematocrit can result
in worsening of ischemia, especially in those animals with
pre-existing heart disease (29). Fourth, reduced hematocrit
may result in ventricular remodeling and cardiac dysfunc-
tion. Chronic anemia is known to result in increased venous
return and increased cardiac work (30), which may lead to
LV hypertrophy and subsequent cardiac enlargement. The
latter is well appreciated in patients with ESRD who are
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anemic secondary to their kidney disease (7,31) but likely
also plays a role in patients with other causes of anemia. As
mentioned previously, our retrospective analysis cannot
distinguish among these four possibilities.
Although anemia was inversely correlated with the level
of kidney function in the SOLVD cohort, the correlation
was weak. The reason for the low correlation in this
cohort is likely due to a combination of lesser degrees of
erythropoietin deficiency with less severe reduction in GFR
and the exclusion of patients with more severe reduction in
GFR. The level of kidney function, therefore, does not
appear to be the primary determinant of hematocrit in this
cohort.
Relationship between level of kidney function and
level of hematocrit on all-cause mortality. Evaluation
of the interaction between the level of hematocrit and the
level of GFR on all-cause mortality suggests that anemia
and reduction in kidney function are more than additive as
risk factors. One could extrapolate this further and propose
that patients with kidney function low enough to cause
erythropoietin deficiency may have two synergistic risk
factors for mortality, namely reduction in GFR as well as
anemia.
Implications. From a treatment standpoint, our results
lead to two questions. First, is it feasible to correct anemia
with erythropoietin in HF patients? The study conducted by
Silverberg et al. (8) would suggest that partial correction of
anemia to a hemoglobin level of 12 g/dl is feasible and safe
in patients with severe HF. Other studies, however, have
documented that erythropoietin levels may already be ele-
vated in patients with severe HF (3) and raise the question
whether additional erythropoietin would be helpful. Evalu-
ating the causes of anemia in patients with HF will be
important in answering this question. Second, assuming
that anemia can be corrected in patients with HF, will
partial or complete correction lower morbidity and mortality
in randomized trials?
Study limitations. There are three potential limitations of
our retrospective analyses. First, the MDRD study predic-
tion equation for GFR has not been validated in patients
with LV dysfunction. Second, the range of hematocrit and
GFR was limited by exclusion criteria, and only a few
patients had severe anemia or severe kidney dysfunction.
Therefore, one needs to be cautious when extrapolating the
results to the extremes. Third, although SOLVD was a
randomized trial, the relationships that we have evaluated
were not the subject of the treatment comparison, and,
therefore, like any observational study, our findings may be
limited by confounding from variables we did not take into
account.
Conclusions. We conclude that a lower level of kidney
function and hematocrit appear to be independent risk
factors for mortality in patients with LV dysfunction.
Furthermore, there appears to be a synergistic relationship
between these risk factors in the lower range of GFR and
hematocrit. Documentation that kidney function is a risk
factor for mortality in patients with LV dysfunction con-
firms previous analyses of SOLVD as well as other HF
studies. The findings that anemia is a risk factor for
mortality and that anemia and reduced kidney function
appear to have a synergistic effect on mortality when both
are compromised need to be confirmed in additional studies.
If these findings are reproduced, then further studies need to
be performed, first to evaluate the causes of anemia in
patients with LV dysfunction and, ultimately, to prospec-
tively evaluate the potential benefit of the correction of
anemia with erythropoeitin.
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